Home Cart Sign in  
Chemical Structure| 1062368-49-3 Chemical Structure| 1062368-49-3

Structure of ML347
CAS No.: 1062368-49-3

Chemical Structure| 1062368-49-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ML347 is a highly selective ALK1/ALK2 inhibitor with IC50s of 46/32 nM and shows > 300-fold selectivity for ALK2 vs. ALK3.

Synonyms: LDN 193719

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ML347

CAS No. :1062368-49-3
Formula : C22H16N4O
M.W : 352.39
SMILES Code : COC1=CC=C(C2=CN3C(N=C2)=C(C4=C5C=CC=NC5=CC=C4)C=N3)C=C1
Synonyms :
LDN 193719
MDL No. :MFCD28099805
InChI Key :FVRYPYDPKSZGNS-UHFFFAOYSA-N
Pubchem ID :44577753

Safety of ML347

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H319-H332-H372-H400
Precautionary Statements:P260-P264-P270-P273-P280-P301+P312+P330-P304+P312-P305+P351+P338-P314-P337+P313-P391-P501
Class:9
UN#:3077
Packing Group:

Isoform Comparison

Biological Activity

Target
  • ALK1

    ALK1, IC50:46 nM

  • ALK2

    ALK2, IC50:32 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
HCT15 25 µM To evaluate the effect of ML347 on HCT15 cells PMC10518977
HUVECs 0.5 or 1 µM 12 h To evaluate the inhibitory effect of ML347 on Dkk-3-mediated VEGF upregulation. The results showed that ML347 exposure abrogated the VEGF upregulation induced by hrDkk-3. PMC5348502
HUVECs 0.5 or 1 µM 12 h To evaluate the inhibitory effect of ML347 on Dkk-3-mediated VEGF upregulation. The results showed that ML347 exposure abrogated the VEGF upregulation induced by hrDkk-3. PMC5348502
C2C12BRA cells 152 nM Evaluate the activity of ML347 in the BMP4 cell assay, showing an IC50 of 152 nM PMC3677712

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Chronic constriction injury (CCI) model Intrathecal injection 100 ng Single injection ML347, as an ALK1 selective inhibitor, was used to determine whether the effects of SIN on CCI mice were mediated through the ALK1 receptor. The results showed that ML347 did not reverse the analgesic effects of SIN, indicating that ALK1 is not involved in the action of SIN. PMC11588427
B-NSG mice Patient-derived xenograft (PDX) model Intraperitoneal injection 45 mg/kg Every other day for 3 weeks To evaluate the effect of ML347 in combination with Regorafenib on tumor growth, results showed that the combination therapy significantly inhibited tumor growth PMC10518977

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.84mL

0.57mL

0.28mL

14.19mL

2.84mL

1.42mL

28.38mL

5.68mL

2.84mL

References

 

Historical Records

Categories